SanBio Co. Ltd.

SanBio Co., Ltd. develops regenerative cell therapies for CNS disorders, with SB623 in Phase 2 for traumatic brain injury and a robust pipeline covering stroke, neurodegeneration, and muscular dystrophy.

Headquarters: Japan (JPN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 29
HQ: Tokyo

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
4592	SanBio Co. Ltd. Cap: 154.8B	EQUITY	JPX	JPY	JP3336750009	Active	📈